Eli Lilly Issues FY26 Guidance

February 04, 2026 — 07:26 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Eli Lilly and Company (LLY) said, for fiscal 2026, the company projects: earnings per share in a range of $33.50 to $35.00, and revenue of $80 to $83 billion. The company expects continued momentum from Mounjaro and Zepbound worldwide, and growth from key products including Ebglyss, Omvoh, Jaypirca, Inluriyo, and Kisunla.

Fourth quarter net income - reported - was $6.64 billion compared to $4.41 billion, a year ago. EPS increased by 51% to $7.39 on a reported basis. EPS increased by 42% to $7.54 on a non-GAAP basis. The company noted that the results are inclusive of $0.52 of acquired IPR&D charges. Analysts on average expected the company to report profit per share of $6.93, for the quarter. Analysts' estimates typically exclude special items. Revenue increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound. Key Products revenue grew to $13.8 billion, led by Mounjaro and Zepbound.

In pre-market trading on NYSE, Eli Lilly shares are up 7.15 percent to $1,075.49.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Eli Lilly Issues FY26 Guidance

Tags

Latest Articles